Impact of Change in Serum Sodium Concentration on Mortality in Patients Hospitalized With Heart Failure and Hyponatremia

被引:61
作者
Madan, Vinay D. [1 ]
Novak, Eric [1 ]
Rich, Michael W. [1 ]
机构
[1] Washington Univ, Sch Med, Div Cardiol, St Louis, MO 63110 USA
关键词
heart failure; hyponatremia; prognosis; VASOPRESSIN ANTAGONIST; INTRAVENOUS MILRINONE; TOLVAPTAN; ACTIVATION; OUTCOMES;
D O I
10.1161/CIRCHEARTFAILURE.111.961011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background-Hyponatremia is a common electrolyte abnormality among patients hospitalized with heart failure and it is a marker for increased short-term and long-term mortality. However, little is known about the time course of hyponatremia and whether changes in serum sodium levels affect clinical outcomes. Methods and Results-Patients (n=322) hospitalized with decompensated heart failure and serum sodium <135 mmol/L were evaluated. After hospital discharge, the first sodium value obtained within a 60- to 270-day period was recorded, and patients were classified into 3 groups, based on whether the serum sodium value increased (>= 2 mmol/L), decreased (<= 2 mmol/L), or remained unchanged (+/- 1 mmol/L) relative to the baseline value. Kaplan-Meier survival curves were constructed to illustrate mortality as a function of change in sodium concentration over time, and a Cox-proportional hazards model was constructed to determine if change in serum sodium concentration predicted mortality after adjusting for relevant covariates. The mean age of the population was 66 years, 45% were women, and 55% were white. The mean baseline sodium level was 131 mmol/L and the mean ejection fraction was 32.5%. Two hundred twenty-two patients (68.9%) exhibited an increase in sodium during follow-up; in 57 patients (17.7%) the level was unchanged and in 43 patients (13.4%) there was a decrease in sodium level. During a median follow-up of 610 days, there was a strong positive association between change in sodium level and survival (P for trend <0.001); that is, increased sodium was associated with decreased mortality. In multivariable analysis, change in sodium concentration and higher blood urea nitrogen were the strongest predictors of mortality (both P<0.0001). Conclusions-Among patients hospitalized with heart failure and hyponatremia, change in serum sodium concentration over time is a strong predictor of long-term survival. (Circ Heart Fail. 2011;4:637-643.)
引用
收藏
页码:637 / 643
页数:7
相关论文
共 25 条
[1]
PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[2]
Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial [J].
Cuffe, MS ;
Califf, RM ;
Adams, KF ;
Benza, R ;
Bourge, R ;
Colucci, WS ;
Massie, BM ;
O'Connor, CM ;
Pina, I ;
Quigg, R ;
Silver, MA ;
Georghiade, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (12) :1541-1547
[3]
[4]
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia [J].
Finley, John J. ;
Konstam, Marvin A. ;
Udelson, James E. .
CIRCULATION, 2008, 118 (04) :410-421
[5]
COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].
FRANCIS, GS ;
BENEDICT, C ;
JOHNSTONE, DE ;
KIRLIN, PC ;
NICKLAS, J ;
LIANG, CS ;
KUBO, SH ;
RUDINTORETSKY, E ;
YUSUF, S .
CIRCULATION, 1990, 82 (05) :1724-1729
[6]
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial [J].
Gheorghiade, M ;
Gattis, WA ;
O'Connor, CM ;
Adams, KF ;
Elkayam, U ;
Barbagelata, A ;
Ghali, JK ;
Benza, RL ;
McGrew, FA ;
Klapholz, M ;
Ouyang, J ;
Orlandi, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1963-1971
[7]
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure -: Results from a double-blind, randomized trial [J].
Gheorghiade, M ;
Niazi, I ;
Ouyang, J ;
Czerwiec, F ;
Kambayashi, J ;
Zampino, M ;
Orlandi, C .
CIRCULATION, 2003, 107 (21) :2690-2696
[8]
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial [J].
Gheorghiade, Mihai ;
Rossi, Joseph S. ;
Cotts, William ;
Shin, David D. ;
Hellkamp, Anne S. ;
Pina, Ileana L. ;
Fonarow, Gregg C. ;
DeMarco, Teresa ;
Pauly, Daniel F. ;
Rogers, Joseph ;
DiSalvo, Thomas G. ;
Butler, Javed ;
Hare, Joshua M. ;
Francis, Gary S. ;
Stough, Wendy Gattis ;
O'Connor, Christopher M. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (18) :1998-2005
[9]
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry [J].
Gheorghiade, Mihai ;
Abraham, William T. ;
Albert, Nancy M. ;
Stough, Wendy Gattis ;
Greenberg, Barry H. ;
O'Connor, Christopher M. ;
She, Lilin ;
Yancy, Clyde W. ;
Young, James ;
Fonarow, Gregg C. .
EUROPEAN HEART JOURNAL, 2007, 28 (08) :980-988
[10]
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials [J].
Gheorghiade, Mihai ;
Konstam, Marvin A. ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Udelson, James E. ;
Zannad, Faiez ;
Cook, Thomas ;
Ouyang, John ;
Zimmer, Christopher ;
Orlandi, Cesare .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12) :1332-1343